Jong, K. Mortelmans, C. Green, Hokama, T. Tran, D. Sahner; SRI Intl., Menlo Park, CA. Nguon H. Chan Fleck Wong

155 TUESDAY SCIENTIFIC SESSIONS Final Program F-1527 In Vitro Synergy Studies with a Promising New Compound, the Tetra- para-Guanidinoethylcalix[4]arene M. Grare 1 , M. Mourer 1 , J. Regnouf-de-Vains 1 , R. E. Duval 1,2 ; 1 UMR 7565, Univ. de Lorraine CNRS, Nancy, France, 2 ABC Platform, Nancy, France. F-1528 In Vitro Activity of C-101 Solution, a New Eosinophil Peroxi- dase EPO Containing Enzyme System against Gram-Negative and Gram-Positive Pathogens

G. A. Denys

1 , D. Shah 2 , D. F. Sahm 2 , R. C. Allen 3 , P. O’Hanley 4 , J. T. Stephens 4 ; 1 Indiana Univ. Hlth., Indianapolis, IN, 2 Eurofins, Chantilly, VA, 3 Creighton Univ. Med. Ctr., Omaha, NE, 4 Exoxemis, Inc., Little Rock, AR. F-1529 Identification of a Novel Anti-PcrV Antibody That Blocks Type Three Secretion and Provides Superior Protection in Pseudo- monas aeruginosa Animal Infection Models P. Warrener, R. Varkey, J. Zha, A. DiGiandomenico, M. Camara, P. Chow- dury, B. Sellman, K. Stover; MedImmune LLC, Gaithersburg. F-1530 Disposition of MGB-BP-3, a New Class of Antibacterial Agent, after Oral Administration in a Hamster Model of Severe Clostridium difficile Associated Diarrhoea CDAD

M. Ravic

1 , C. Suckling 2 , I. Hunter 2 , C. Gemmell 3 , P. Warn 4 , A. Sattar 4 , M. Saunders 5 ; 1 MGB Biopharma, Glasgow, United Kingdom, 2 Univ. of Strathclyde, Glasgow, United Kingdom, 3 Univ. of Glasgow and Strathclyde, Glasgow, United Kingdom, 4 Euprotec, Manchester, United Kingdom, 5 Kue- cept, Potters Bar, United Kingdom. F-1531 SRI-011225, a First-in-Class Bactericidal Antimicrobial Active against Drug-Resistant Pathogens L. Jong, K. Mortelmans, C. Green, L. Hokama, T. Tran, D. Sahner; SRI Intl., Menlo Park, CA. F-1532 In Vitro Antimicrobial Effect of Diacetyl Rhein

S. Nguon

1,2 , J. Novakova 2 , L. Kokoska 2 ; 1 Royal Univ. of Agriculture, Phnom Penh, Cambodia, 2 Czech Univ. of Life Sci. Prague, Czech Republic. F-1533 Antibacterial and Antifungal Activity of 2-S-Nitrobenzyl- Substituted Halogenobenzimidazoles A. E. Laudy 1 , E. Swietochowska 1 , M. Kozlowska 2 , Z. Kazimierczuk. 2 , S. Tyski 1,3 ; 1 Med. Univ. of Warsaw, Warsaw, Poland, 2 Warsaw Univ. of Life Sci., Warsaw, Poland, 3 Natl. Med.s Inst., Warsaw, Poland. F-1534 Computational Design of Staphylococcus aureus SrtA Enzyme Inhibitors

A. H. Chan

1 , E. M. Weiner 1 , J. Wereszczynski 2 , J. A. McCammon 2 , R. T. Clubb 1 ; 1 Univ. of California, Los Angeles, Los Angeles, CA, 2 Univ. of Cali- fornia, San Diego, CA. F-1535 Identifying and Characterizing Inhibitors of Streptococcus pneumoniae Enda Using a Novel PicoGreen Nuclease Assay E. J. R. Peterson, D. Kireev, W. P. Janzen S. F. Singleton; Univ. of North Carolina, Chapel Hill, NC. F-1536 Screening for Broad Spectrum Antimicrobials with Unknown Targets

L. Fleck

1 , G. Casadei 2 , K. Lewis 1 ; 1 Northeastern Univ., Boston, MA, 2 The Lombardy and E. Romagna Zootechnic Inst., Parma, Italy. F-1537 Developing Synthetic Antibodies against Clostridium difficile Toxins as a Potential Therapeutic

S. Wong

1 , P. Papatheodorou 2 , T. Brummelkamp 3 , B. Nelson 1 , D. van Dyk, K. Aktories 2 , S. Sidhu 1 , J. Moffat 1 ; 1 Univ. of Toronto, Toronto, Canada, 2 Univ. of Freiburg, Freiburg, Germany, 3 Netherlands Cancer Inst., Amsterdam, Netherlands. F-1538 High-Throughput Screening for Novel Antimicrobial Agents Using a Whole Animal Infection Model B. Fuchs 1 , Y. Kim 1 , J. Larkins-Ford 1 , A. Conery 1 , F. Ausubel 1 , E. Mylona- kis 2 ; 1 Massachusetts Gen. Hosp., Boston, MA, 2 Brown Univ., Providence, RI. F-1539 Inhibition of Cell Division Induced by External Guide Se- quences Targeting ftsz C. Davies Sala 1 , A. Soler Bistué 1,2 , L. Korprapun 1 , A. Zorreguieta 1 , M. Tolmasky 2 ; 1 Fundación Inst. Leloir IIBBA CONICET UBA, Buenos Aires, Argentina, 2 California State Univ. Fullerton, CA. F-1540 Residues of Phosphopantetheine Adenylyltransferase That Determine Susceptibility to the Inhibitor N-Fmoc-L-glutamyl- D-histidine Isobutylamide A. R. Akin 1 , M. F. Hollis-Symynkywicz 2 , W. Shu 1 , K. Suefuji 1 , L. Xie 1 , D. N. Chin 2 , B. A. Appleton 1 , C. J. Balibar 1 ; 1 Novartis Inst. BioMed. Res., Emeryville, CA, 2 Novartis Inst. BioMed. Res., Cambridge, MA. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program. ------------------------------------------------------------------------ 178G3 Poster Session Pediatrics Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: G3-1541 Bacterial Meningitis and Pneumococcal Serotype Distribu- tion in Children in Cameroon

A. Gervaix